📊 MIST Key Takeaways
Is Milestone Pharmaceuticals Inc. (MIST) a Good Investment?
Milestone Pharmaceuticals exhibits critical commercial failure indicators with only $238K in revenue while losses deteriorated 51.9% YoY to -$26.1M, signaling failed product commercialization or market adoption. Negative operating cash flow of -$16.1M coupled with inability to service debt (interest coverage of -27.1x) indicates the company operates unsustainably on existing cash reserves. Despite adequate near-term liquidity, the worsening trajectory and elevated debt-to-equity ratio of 1.61x suggest inevitable dilutive equity raises or restructuring.
Milestone Pharmaceuticals shows the classic profile of a pre-revenue biotech with no operating income, persistent net losses, and materially negative free cash flow. While liquidity is currently strong with $73.05M in cash and high current/quick ratios, the combination of a roughly $49M annual operating cash burn and $57.19M of long-term debt creates meaningful financing and balance-sheet risk if commercialization or regulatory progress is delayed.
Why Buy Milestone Pharmaceuticals Inc. Stock? MIST Key Strengths
- Cash position of $71.3M provides 4-5 year operational runway at current burn rate
- Excellent liquidity ratios (9.18x current ratio) eliminate immediate solvency risk
- Minimal capital expenditure ($45K) suggests asset-light development model
- Strong near-term liquidity with 8.01x current ratio and $73.05M cash balance
- Asset base still exceeds liabilities, leaving positive stockholders' equity of $41.77M
- Net loss was essentially stable year over year, suggesting some cost containment versus a worsening loss profile
MIST Stock Risks: Milestone Pharmaceuticals Inc. Investment Risks
- Revenue of only $238K indicates failed or stalled commercial product launch
- Net losses worsening 51.9% YoY demonstrates deteriorating business trajectory, not typical biotech development curve
- Negative operating cash flow of -$16.1M with interest coverage of -27.1x means company cannot service debt from operations
- Debt-to-equity of 1.61x unsustainable for pre-commercial biotech; equity dilution likely inevitable
- Negative ROE (-72.3%) and ROA (-13.5%) destroying shareholder value systematically
- Deteriorating EPS (-11.9% YoY) indicates worsening per-share economics
- No revenue base, leaving the business fully dependent on external funding and pipeline execution
- Heavy cash burn with negative operating cash flow of $49.04M and free cash flow of $49.34M
- Leverage is meaningful for a loss-making company, with debt/equity of 1.37x and negative interest coverage
Key Metrics to Watch
- Quarterly revenue growth trajectory and product adoption rates
- Operating cash flow inflection point toward positive territory
- Cash burn rate trend and months of runway remaining
- Debt refinancing events and dilutive equity financing announcements
- Regulatory approval status and pipeline advancement for lead products
- Cash runway relative to quarterly operating cash burn
- Revenue generation or regulatory/commercial milestones that can validate the path to profitability
Milestone Pharmaceuticals Inc. (MIST) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.18x current ratio provides a solid financial cushion.
MIST Profit Margin, ROE & Profitability Analysis
MIST vs Healthcare Sector: How Milestone Pharmaceuticals Inc. Compares
How Milestone Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Milestone Pharmaceuticals Inc. Stock Overvalued? MIST Valuation Analysis 2026
Based on fundamental analysis, Milestone Pharmaceuticals Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Milestone Pharmaceuticals Inc. Balance Sheet: MIST Debt, Cash & Liquidity
MIST Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Milestone Pharmaceuticals Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.67 indicates the company is currently unprofitable.
MIST Revenue Growth, EPS Growth & YoY Performance
MIST Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$20.8M | $-0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Milestone Pharmaceuticals Inc. Dividends, Buybacks & Capital Allocation
MIST SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Milestone Pharmaceuticals Inc. (CIK: 0001408443)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MIST
What is the AI rating for MIST?
Milestone Pharmaceuticals Inc. (MIST) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MIST's key strengths?
Claude: Cash position of $71.3M provides 4-5 year operational runway at current burn rate. Excellent liquidity ratios (9.18x current ratio) eliminate immediate solvency risk. ChatGPT: Strong near-term liquidity with 8.01x current ratio and $73.05M cash balance. Asset base still exceeds liabilities, leaving positive stockholders' equity of $41.77M.
What are the risks of investing in MIST?
Claude: Revenue of only $238K indicates failed or stalled commercial product launch. Net losses worsening 51.9% YoY demonstrates deteriorating business trajectory, not typical biotech development curve. ChatGPT: No revenue base, leaving the business fully dependent on external funding and pipeline execution. Heavy cash burn with negative operating cash flow of $49.04M and free cash flow of $49.34M.
What is MIST's revenue and growth?
Milestone Pharmaceuticals Inc. reported revenue of $238.0K.
Does MIST pay dividends?
Milestone Pharmaceuticals Inc. does not currently pay dividends.
Where can I find MIST SEC filings?
Official SEC filings for Milestone Pharmaceuticals Inc. (CIK: 0001408443) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MIST's EPS?
Milestone Pharmaceuticals Inc. has a diluted EPS of $-0.20.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MIST a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Milestone Pharmaceuticals Inc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MIST stock overvalued or undervalued?
Valuation metrics for MIST: ROE of -72.3% (sector avg: 15%), net margin of -10,952.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MIST stock in 2026?
Our dual AI analysis gives Milestone Pharmaceuticals Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MIST's free cash flow?
Milestone Pharmaceuticals Inc.'s operating cash flow is $-16.1M, with capital expenditures of $45.0K. FCF margin is -6,763.9%.
How does MIST compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -10,952.1% (avg: 12%), ROE -72.3% (avg: 15%), current ratio 9.18 (avg: 2).
Is Milestone Pharmaceuticals Inc. carrying too much debt?
MIST has a debt-to-equity ratio of 1.61x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 9.18 suggests adequate short-term liquidity.